Comparative Brain Tumor Consortium

比较脑肿瘤联盟

• 批准号: 10926276
• 负责人: Amy Leblanc
• 金额: $ 11.38万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926276
• 关键词: Adult; Adult Glioma; Affect; Ally; American; Apoptosis; Area; Astrocytoma; Basic Science; Biopsy; Brain Neoplasms; Breeding; CCR; California; Canis familiaris; Catalogs; Cell Line; Central Nervous System; Characteristics; Childhood Glioma; Classification; Classification Scheme; Clinical; Clinical Trials; Collaborations; Companions; Comparative Pathology; Consensus; Data; Data Commons; Development; Diagnosis; Discipline; Disease; Early Diagnosis; Enrollment; Event; Excision; Expression Profiling; Extramural Activities; Face; Freezing; Funding; Future; Genomics; Glass; Glioma; Goals; Grant; Group Structure; Hematoxylin and Eosin Staining Method; Histologic; Histology; Histopathology; Human; Illinois; Image; Immunotherapeutic agent; Incidence; Income; Informatics; Infrastructure; Institution; Internal Medicine; Joints; Journals; Knowledge; Link; Magnetic Resonance Imaging; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of brain; Manuscripts; Medicine; Methylation; Modeling; Molecular; Molecular Profiling; Morbidity - disease rate; National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; Nature; Neurologist; Neurology; Oncology; Operative Surgical Procedures; Outcome; PAC1 phosphatase; Paper; Pathologic; Pathology; Patient Care; Patients; Physicians; Pituitary Neoplasms; Play; Positron-Emission Tomography; Pre-Clinical Model; Prevention; Procedures; Process; Publications; Publishing; Radiology Specialty; Reporting; Research; Research Personnel; Role; Slide; Specialist; Stains; Surveys; TP53 gene; Texas; The Jackson Laboratory; Time; Tissues; Training; United States National Institutes of Health; Universities; University of Minnesota Cancer Center; Update; Veterinarians; Veterinary Medicine; cancer cell; college; comparative; disease natural history; drug development; drug discovery; exome sequencing; experience; glioma cell line; high-throughput drug screening; human disease; human model; imaging agent; improved; improved outcome; interest; irradiation; meetings; member; meningioma; neuro-oncology; neuropathology; novel; oligodendroglioma; oncology program; pharmacologic; prospective; small molecule; statistics; stem cells; transcriptome sequencing; tumor; ultrasound; working group

The COP has made significant progress on the inaugural comparative pathology effort for this new initiative in 2018, with a publication currently in review at the Journal of Neuropathology and Experimental Neurology. The pathology board, consisting of a joint veterinary/physician neuropathology commission of 14 members, developed an updated grading and classification scheme for canine gliomas to promote uniformity in diagnosis across institutions and improve making comparisons with human adult and childhood gliomas. A retrospective pathologic assessment of approximately 200 hematoxylin and eosin stained glass slides + a panel of 5 IHC markers treatment-naive canine gliomas of all subtypes and grades has been conducted. The CBTC membership has also proposed genomic analyses and expression profiling of a minimum of 50 canine high-grade gliomas meeting these newly revised classification criteria to allow for comparison with human adult and childhood gliomas, and to generate potential pharmacologic targets for canine patients. This project will be both retrospective and prospective in nature. For the retrospective portion, snap-frozen tissue from institutions with paired banked FFPE tissue from histopathology-confirmed glial tumors that have been confirmed within the newly proposed grading and classification scheme, will be subjected to whole-exome sequencing and RNA-seq. For the prospective portion, CBTC members (Texas A&M University/MD Anderson Cancer Center, University of Minnesota, and University of Califnornia @ Davis) have partnered with Roel Verhaak at the Jackson laboratory. Dr Verhaak is working with these CBTC members, whom have received NCI funding through a P30 CC supplemental mechanism, to generate molecular profiles from an overlapping set of canine gliomas, which will include WGS/WES/RNAseq and methylation profiling data. Sequence information was subjected to informatics, processed, and shared publicly through the NCI Integrated Canine Data Commons (ICDC) and published in Cancer Cell. We have also initiated several other projects in this area, which are listed here: 1. Whole-exome and RNA sequencing of n = 100 canine meningiomas (in collaboration with Peter Dickinson at UC-Davis, M. Renee Chambers at UAB and Greg Tawa/NIH/NCATS 2. Survey instrument to veterinary neurologists in the US to capture the clinical landscape of canine brain tumor management 3. High-throughput drug screening of P53 w/t canine and childhood glioma cell lines 4. A clinical trial of a novel capsize-3 activating small molecule (PAC-1) in dogs with meningioma, which is linked to assessment of a novel apoptosis-reporting PET imaging agent (in collaboration with NHLBI/IPDC, NCI/CCR/MIP, and University of Illinois. 5. MRI consensus statement on harmonization of imaging parameters for dogs enrolled in brain tumor clinical trials (manuscript published in Veterinary Radiology and Ultrasound). New projects proposed for 2018- beyond include: a companion comparative histologic and molecular characterization project in canine meningioma; extension of the HTS project with NCATS to include 5 new canine glioma stem cell lines generated at Univ of CA-Davis, and a bi-monthly WebEx to offer continuing exchange of ideas and projects among interested CBTC members.

COP在2018年的这项新计划的首届比较病理学工作中取得了重大进展，目前在《神经病理学与实验神经病学杂志》上进行了综述。病理委员会由14名成员的联合兽医/医师神经病理学委员会组成，为犬Gliomas开发了更新的分级和分类方案，以促进机构跨机构诊断的统一性，并改善与人类成人和儿童胶质瘤的比较。已经进行了大约200个苏木精和曙红染色的载玻片 +一个5 IHC标记的面板的回顾性病理评估。 CBTC成员还提出了符合这些新修订的分类标准的至少50个犬高级神经胶质瘤的基因组分析和表达分析，以允许与人类和儿童的神经胶质瘤进行比较，并为犬类患者产生潜在的药理靶标。这个项目本质上是回顾性的，也是潜在的。对于回顾性部分，将在新提出的分级和分类方案中确认的组织病理学确认的神经胶质肿瘤的机构的机构中的冻结组织将受到全外活体测序和RNA-sequencing和RNA-seq。对于潜在的部分，CBTC成员（得克萨斯州A＆M大学/MD Anderson癌症中心，明尼苏达大学和加利福尼亚大学 @ Davis）与Roel Verhaak合作在杰克逊实验室。 Verhaak博士正在与这些CBTC成员合作，这些CBTC成员通过P30 CC补充机制获得了NCI资金，以从一组重叠的犬Gliomas集中产生分子曲线，其中包括WGS/WES/RNASEQ和甲基化数据。序列信息受到信息学的影响，通过NCI集成犬数据共享（ICDC）公开处理和共享，并在癌细胞中发布。 We have also initiated several other projects in this area, which are listed here: 1. Whole-exome and RNA sequencing of n = 100 canine meningiomas (in collaboration with Peter Dickinson at UC-Davis, M. Renee Chambers at UAB and Greg Tawa/NIH/NCATS 2. Survey instrument to veterinary neurologists in the US to capture the clinical landscape of canine brain tumor management 3. High-throughput drug p53 W/T犬和儿童胶质瘤细胞系4。脑膜瘤狗的新型CapSize-3激活小分子（PAC-1）的临床试验，该试验与对新型凋亡报告的pet pet Imaging剂的评估有关（NHLBI/IPDC/ipdc/ipdc/ccr/ccr/ccr/mip ininlino consens andino cornino consens and Illino conserss and Illino consers and Illino conserss and Illino consers and Illino corminian和Simply simply consimens consersion consersy consermiss consers inlino。参加脑肿瘤临床试验的狗的成像参数（在兽医放射学和超声波上发表的手稿）。使用NCAT的HTS项目扩展，包括在CA-DAVIS的Univ产生的5个新犬神经胶质瘤干细胞系，以及一个每两个月的Webex，可在有兴趣的CBTC成员中持续交流思想和项目。

项目成果

Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.

• DOI: 10.1111/vco.12677
• 发表时间: 2021-06
• 期刊: Veterinary and comparative oncology
• 影响因子: 2.1
• 作者: LeBlanc AK;Atherton M;Bentley RT;Boudreau CE;Burton JH;Curran KM;Dow S;Giuffrida MA;Kellihan HB;Mason NJ;Oblak M;Selmic LE;Selting KA;Singh A;Tjostheim S;Vail DM;Weishaar KM;Berger EP;Rossmeisl JH;Mazcko C
• 通讯作者: Mazcko C